This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

 Reply to Letter to the Editor "Metrifonate for Alzheimer's Disease Patients"

Murray A. Raskind and Pamela A. Cyrus

Published: August 31, 2000

Article Abstract

Letter to the Editor

Sir: We would like to respond to Dr. Schneider’s commentson our article. For regulatory reasons, the Alzheimer’s DiseaseAssessment Scale-Cognitive subscale (ADAS-Cog) and ClinicianInterview-Based Impression of Change with Caregiver Input(CIBIC-Plus) are generally the primary outcome measures.It has become increasingly apparent that these primary efficacyvariables do not describe the total symptomatic profile of Alzheimer’s disease, and, therefore, the secondary outcomes werereported in our article with equal prominence to scores on theADAS-Cog and the CIBIC-Plus.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 61

Quick Links: Uncategorized

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Skeletal and Dental Fractures Associated With Electroconvulsive Therapy

Recent data suggest the risk of skeletal or dental fracture with ECT may be as low as...

Read More...